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Abstract
 
IgG1, IgG2a, and IgG2b, passively administered with soluble Ags, enhance specific Ab re-
sponses. The effect of IgG3 in this type of feedback regulation has not been studied previously.
We immunized mice with trinitrophenyl (TNP)-coupled carrier proteins (bovine serum albu-
min [BSA] or ovalbumin [OVA]) alone or complexed to monoclonal TNP-specific IgG3. The
carrier-specific Ab responses were enhanced by several hundred-fold by IgG3. Enhancement
was significantly impaired in mice depleted of complement factor C3 and in mice lacking com-
plement receptors 1 and 2 (Cr2
 
 
 
/
 
 
 
). In contrast, mice lacking the common Fc-receptor gamma
chain (FcR
 
 
 
 
 
/
 
 
 
), resulting in reduced expression of Fc
 
 
 
RI and lack of Fc
 
 
 
RIII, and mice lack-
ing Fc
 
 
 
RIIB (Fc
 
 
 
RIIB
 
 
 
/
 
 
 
), responded equally well to immunization with IgG3-complexed
Ag as wild-type controls. These findings demonstrate that IgG3 can induce feedback enhance-
ment and that IgG3, in analogy with IgM, uses the complement system for this function.
Key words: rodents • Fc receptors • cellular activation • transgenic/knockout
 
Introduction
 
IgG3 is the predominant IgG subclass in responses against T
cell–independent type 2 antigens in mice whereas it consti-
tutes a very low fraction of IgG responses to T cell–depen-
dent protein Ags (1, 2). A similar situation is seen with hu-
man IgG2 which is considered to be the equivalent of
murine IgG3 (3, 4). These isotypes have been postulated to
play an important biological role in the defense against bac-
terial infections. In support of this, IgG3-deficient mice
were shown to be more susceptible to pneumococcal sepsis
than wild-type animals (5). IgG3 Abs are efficient activators
of C, and although they were first believed to act only via
the alternative pathway, it was recently shown that mono-
clonal anti-erythrocyte IgG3 can activate the classical path-
way (6). Some biological functions of IgG3 are dependent
on C activation, such as the protective effect against 
 
Can-
dida albicans
 
 infections and the pathogenicity in hemolytic
anemia (6, 7). Another possible effector pathway of IgG3 is
via Fc-receptors (FcRs).
 
*
 
 
 
Early studies demonstrated that
macrophages could phagocytose IgG3-coated particles and
suggested the existence of a specific FcR for IgG3 (8). This
receptor has been elusive, and for many years IgG3 was not
believed to bind to any of the known murine Fc-receptors
for IgG (Fc
 
 
 
RI, Fc
 
 
 
RIIB, or Fc
 
 
 
RIII; reference 9). How-
ever, recent data suggest that Fc
 
 
 
RI is the IgG3-binding
receptor (10, 11).
Apart from mediating various effector functions, Abs
have the ability to feedback regulate the production of
themselves (for a review, see reference 12). Passively ad-
ministered, or actively produced, specific Ab can enhance
or suppress Ab responses to the Ag they bind to. Regula-
tion is potent, frequently resulting in 99% suppression or
several 100-fold enhancement, and only responses to deter-
minants within the immune complex are affected. When
TNP-specific IgG1, IgG2a, IgG2b, or IgE are administered
together with soluble hapten-carriers, e.g. OVA-TNP,
BSA-TNP, or KLH-TNP, the anti-carrier responses are
enhanced (13–15). Enhancement by IgG2a and IgG1 takes
place in the absence of C activation (16) and in Cr2
 
 
 
/
 
 
 
mice lacking CR1 (CD35) and CR2 (CD21; reference
17), but is severely impaired in FcR
 
 
 
 
 
/
 
 
 
 mice (14). These
mice lack the common signaling 
 
 
 
-chain used by both
Fc
 
 
 
RI and Fc
 
 
 
RIII and do not express Fc
 
 
 
RIII (18), al-
though 1/5 of Fc
 
 
 
RI was recently shown to remain (11).
The data therefore suggest an important role for Fc
 
 
 
Rs in
IgG1- and IgG2a-mediated enhancement. IgE-mediated
enhancement is exclusively dependent on the low affinity
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Abbreviations used in this paper:
 
 BCR, B cell receptor; CVF, cobra
venom factor; FcR, Fc-receptor.T
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receptor for IgE, CD23 (15, 19, 20). Also, IgM can en-
hance Ab responses and this effect is dependent on C acti-
vation. Mutant monoclonal IgM that has lost its ability to
activate C cannot enhance, normal IgM cannot enhance in
C-depleted mice or in Cr2
 
 
 
/
 
 
 
 mice lacking CD35 and
CD35 (17, 21), and monomeric IgM, which cannot acti-
vate C, does not enhance (22). Murine CD21 and CD35
are alternatively spliced from the same Cr2 gene and knock-
out mice therefore lack both receptors (23, 24). CD21 asso-
ciates with the signaling molecule CD19 in the B cell mem-
brane and cocrosslinking of the B cell receptor (BCR) and
CD21/CD19 lowers the threshold for B cell activation (25).
Cr2
 
 
 
/
 
 
 
 mice have poor Ab responses to suboptimal doses of
various antigens (for a review, see references 23 and 24) and
it was recently shown that IgG3 was the most severely af-
fected isotype (26). These mice were more susceptible to
 
Streptococcus pneumoniae
 
 infection than wild-type controls
(26), a finding agreeing well with a role for IgG3 (5) and C3
(27) in defense against bacterial infections.
Whether IgG3, in addition to the isotypes discussed
above, can act to enhance humoral responses has not been
examined. We here report that TNP-specific IgG3 mAbs,
administered in complex with BSA-TNP or OVA-TNP,
dramatically increase the carrier-specific responses, some-
times 
 
 
 
1,000-fold. IgG3 enhances Ab responses equally
well in FcR
 
 
 
 
 
/
 
 
 
 and Fc
 
 
 
RIIB
 
 
 
/
 
 
 
 as in wild-type control
mice. In contrast, the capacity of IgG3 to enhance Ab pro-
duction was markedly reduced in C3-depleted as well as in
Cr2
 
 
 
/
 
 
 
 mice, suggesting that IgG3, in analogy with IgM,
enhances the Ab response via the C system.
 
Materials and Methods
 
Antigens.
 
BSA (fraction V, A-3059), OVA (grade V,
A-5553), and TNP (picrylsulfonic acid/hydrate) were from
Sigma-Aldrich and KLH from Calbiochem. TNP was conjugated
to BSA or OVA as described (28). The number of TNP residues/
Ag molecule was 12 for BSA and 3 for OVA determined accord-
ing to (29). SRBC from the National Veterinary Institute (Upp-
sala, Sweden), were conjugated to TNP (SRBC-TNP) as de-
scribed (30).
 
Antibodies.
 
5-mo-old BALB/c mice (Bommice) were immu-
nized in the tail vein with 4 
 
 
 
 10
 
8
 
 SRBC-TNP in 0.1 ml PBS.
3 d before the fusion, mice were boosted intravenously with 4 
 
 
 
10
 
8
 
 SRBC-TNP and 10 
 
 
 
g LPS (Sigma-Aldrich) intraperito-
neally. Splenocytes were mixed with the fusion partner Sp 2/0 in
a ratio of 5:1 in PBS containing 50% polyethylene glycol 4000
(Merck), at 37
 
 
 
C for 1 min. The fusion mixture was slowly di-
luted with serum-free DMEM, spun down, and incubated for 15
min at 37
 
 
 
C. The cells were then washed and diluted in DMEM
containing 10% heat-inactivated FCS, seeded out in 96-well mi-
crotiter plates (Nunc), and cultured overnight at 37
 
 
 
C together
with 3 
 
 
 
 10
 
6
 
 rat thymocytes per ml. Next day, HAT (Hypoxan-
thine-Aminopterin-Thymidine) medium (Sigma-Aldrich) was
added and the cells were cultured in HAT until growing clones
were established. Hybridomas were screened for production of
IgG3 anti-TNP by ELISA. Positive hybridomas were expanded
and cloned by limiting dilution and clones IM-F10 and IM-H11
were selected for further studies.
IgG3 anti-TNP (IM-F10 and IM-H11), IgG2a anti-TNP
(C4007B4, 7B4; reference 13), and IgE anti-TNP (IgEL-A5,
mouse IgE/
 
 
 
; reference 31) were cultured in DMEM (4.5 g/liter
glucose) supplemented with 50 IU/ml penicillin, 50 
 
 
 
g/ml strep-
tomycin, 2 mM 
 
l
 
-glutamin, 10 mM HEPES, 0.05 mM 2-mer-
captoethanol, and 5% heat-inactivated FCS. IgG mAbs were pu-
rified on a protein A Sepharose column (Amersham Biosciences)
and IgE on a Sepharose column coupled with monoclonal rat
anti–mouse 
 
 
 
 187.1.10 as described (17). Abs were concentrated
by Microsep
 
®
 
 10K concentrator (Pall Filtration Corp.) and the
storage buffer was changed to PBS using a PD10 column (Amer-
sham Biosciences). Protein concentrations were determined by
absorbance at 280 nm, assuming that an absorbance of 1.5 equals
1 mg/ml of Ab. The subclasses of each IgG preparation were
confirmed by subclass-specific ELISA. mAbs were sterile filtered
and IgG2a and IgE stored at –20
 
 
 
C whereas IgG3 was used im-
mediately or stored in liquid nitrogen.
 
Mice.
 
BALB/c, CBA/J, and DBA/1 were from Bommice.
H-2
 
b
 
 mice have an I-A
 
b
 
-linked low responsiveness to IgE/BSA-
TNP and IgG/BSA-TNP complexes (28, 32) and the knockout
mice used in the present study were backcrossed to responder
strains. FcR
 
 
 
 
 
/
 
 
 
 mice (18) were backcrossed/intercrossed to
DBA/1 (H-2
 
q
 
) for five generations and offspring from homozy-
gous mutant FcR
 
 
 
 
 
/
 
 
 
/ H-2
 
q
 
 and wild-type FcR
 
 
 
 
 
/
 
 
 
/H-2
 
q
 
 ani-
mals were used in experiments. Fc
 
 
 
RIIB
 
 
 
/
 
 
 
 mice (33) were
backcrossed to CBA/J mice (H-2
 
k
 
). The fifth generation was in-
tercrossed and offspring from homozygous mutant Fc
 
 
 
RIIB
 
 
 
/
 
 
 
/
H-2
 
k
 
 and wild-type Fc
 
 
 
RIIB
 
 
 
/
 
 
 
/H-2
 
k
 
 mice were used in exper-
iments. Cr2
 
 
 
/
 
 
 
 mice (34), first backcrossed to H-2
 
k
 
 mice (17),
were further backcrossed to DBA/1. Mice from the second gen-
eration were intercrossed and offspring from homozygous mutant
Cr2
 
 
 
/
 
 
 
/H-2
 
q
 
 and wild-type Cr2
 
 
 
/
 
 
 
/H-2
 
q
 
 animals, identified by
PCR analysis (described below), were used in experiments. Mice
were bred and maintained at the Department of Genetics and Pa-
thology, the Department of Animal Development and Genetics
or at the Biomedical Center, Uppsala University.
 
PCR Reactions.
 
The FcR
 
 
 
 genotype was analyzed according
to (18), Fc
 
 
 
RIIB as described (35), and H-2
 
k
 
, H-2
 
b
 
, and the Cr2
genotype according to (17). H-2
 
q
 
 was analyzed in a PCR reac-
tion using two primers: 
 
 
 
K1:2 (5
 
 
 
 TAT CAG TCT CCT GGA
GAC ATT G 3
 
 
 
) and q2 (5
 
 
 
 GTC AAA GCT TGT CAA TTG
GC 3
 
 
 
) resulting in a 128 bp band. Gene amplification was done
in 20 
 
 
 
l 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 5 mM MgCl
 
2
 
,
0.2 mM dNTPs, 0.22 
 
 
 
M of primers, and 2.5 U AmpliTaq
DNA polymerase (PerkinElmer) for 35 cycles (30 s, 94
 
 
 
C; 40 s,
54
 
 
 
C; 50 s, 72
 
 
 
C).
 
Immunizations.
 
Mice were immunized in the tail vein with
Ag alone or Ab/Ag complexes in 0.2 ml PBS. Complexes were
formed by incubating TNP-conjugated Ag with TNP-specific
mAb for 1 h at 37
 
 
 
C, immediately before the immunization.
Non-crossreacting Ag (unconjugated OVA, BSA, or KLH) was
included in the Ag mixture as a specificity control.
 
Cobra Venom Factor Treatment.
 
Mice were injected intraperi-
toneally with four doses of 0.1 ml of 100 U/ml cobra venom fac-
tor (CVF) from 
 
Naja haje
 
 (Cordis Laboratories Inc.) during 24 h.
Control groups received PBS in the same regimen. All mice were
bled individually from the tail 7 d before the first and 2 h after the
last CVF injection. C3 levels in sera were assayed by radial im-
munodiffusion using a polyclonal goat anti-mouse C3 antiserum
(Cooper Biomedical, Inc.). Titers are expressed as the reciprocal
of the highest dilution giving a precipitation line (e. g. dilution
1:27 
 
 
 
 27).
 
ELISA.
 
Blood was collected from tail veins and sera were
tested using IgG anti-BSA-, IgG anti-KLH, or IgG anti-OVA-T
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specific ELISAs (36). Statistical differences were determined by
Student’s 
 
t
 
 test. P values are presented as: not significant, NS; P
 
  
0.05, *; P   0.01, **; P   0.001, ***. Stimulation indices (SI)
were calculated as the geometrical mean of the experimental
group divided by the geometrical mean of the control group.
Hemolysis. Hemolytic titers are defined as the highest anti-
body dilution able to lyse a 0.25% suspension of SRBC-TNP5
(prepared as described [30] but with a fivefold lower concentra-
tion of picryl sulfonic acid) in the presence of a 1:160 dilution of
guinea pig serum in veronal-buffered saline (VBS). Alternative
pathway activation was assayed in VBS with Mg-EGTA (37).
Results
Monoclonal TNP-specific IgG3 Enhances Ab Responses to
BSA-TNP and OVA-TNP. To assess the ability of IgG3
to augment Ab production, mAbs IM-F10 and IM-H11
were administered to CBA/J mice together with BSA-
TNP and OVA. Both mAbs were able to enhance the IgG
anti-BSA responses (51- and 13-fold respectively) com-
pared with control groups immunized with Ag alone (Ta-
ble I, experiments 1 and 2). The response to OVA, in-
cluded as a specificity control, was not affected by IgG3.
Ab responses to BSA in two other strains of mice, BALB/c
and DBA/1, were also efficiently enhanced by IgG3 (1344-
and 316-fold, respectively; Table I, experiments 3 and 4).
IM-F10 administered to BALB/c mice together with an-
other Ag, OVA-TNP, induced an 81-fold enhancement of
the OVA-specific response (unpublished data). Thus, two
out of two TNP-specific IgG3 mAbs were able to specifi-
cally enhance Ab responses to BSA-TNP or OVA-TNP in
three different mouse strains.
Impaired Ab Responses to IgG3/Ag Complexes in C3-depleted
and Cr2 /  Mice. The hemolytic titer of purified IgG3
(1.8 mg/ml) in the presence of Ca2  and Mg2  (both re-
quired for C activation via the classical pathway) was 1:256
whereas the titer in the absence of Ca2  (allowing only al-
ternative pathway activation) was reduced to  1:4. This
established that IM-F10 is an efficient activator of the clas-
sical pathway, confirming previous data (6).
We next examined whether IgG3-mediated enhance-
ment was C dependent. Mice where the MHC-II I-A re-
gion is of the b haplotype are low-responders to IgE/Ag
(28), IgG2a/Ag (32), and IgG3/Ag (unpublished data).
Available C3 and C4-deficient mice are on C57BL/6 and/
or 129/Sv (H-2b) backgrounds. Since the C4 locus is lo-
cated within the MHC region, backcrossing to a responder
MHC is impossible. The C3 locus is located outside, but
close to, the MHC region, and backcrossing to a responder
MHC is feasible, albeit complicated. An alternative ap-
proach is to deplete mice of C3 using CVF which acts by
Table I. Enhancement of Ab Responses by Monoclonal IgG3 Ab
IgG anti-BSA IgG anti-OVA
Exp Strain Immunization
Log10 ng/ml   SD
(geom. mean)a SIb Pc
Log10 ng/ml   SD
(geom. mean)a SIb Pc
1 CBA/J BSA-TNP   OVA 2.25   0.35
(178)
1 c 1.64   0.08
(44)
1c
BSA-TNP   OVA  
50  g IgG3 (IM-F10)
3.96   0.26
(9,076)
51  0.001 1.54   0.11
(35)
0.8 NS
2 CBA/J BSA-TNP   OVA 2.20   0.15
(160)
1 c 2.92   0.19
(830)
1c
BSA-TNP   OVA  
50  g IgG3 (IM-H11)
3.30   0.52
(2,010)
13  0.005 2.81   0.11
(650)
0.8 NS
3 BALB/c BSA-TNP + OVA 2.46   0.40
(290)
1 c 1.98   0.14
(97)
1c
BSA-TNP   OVA  
50  g IgG3 (IM-F10)
5.59   0.15
(389,814)
1,344  0.001 1.74   0.21
(54)
0.6 NS
4 DBA/1 BSA-TNP + OVA 2.41   0.05
(259)
1 c 2.21   0.12
(162)
1c
BSA-TNP   OVA  
50  g IgG3 (IM-F10)
4.91   0.43
(81,835)
316  0.001 2.38   0.07
(240)
1.5 NS
Groups of five mice were immunized intravenously with 20  g BSA-TNP   20  g OVA, alone or together with 50  g TNP-specific mAb IgG3,
IM-F10 or IM-H11. 14 d after immunization, mice were bled and sera tested in ELISA. 
aMean of log10 ng/ml for IgG anti-BSA or IgG anti-OVA. Figures within parentheses represent geometrical mean (anti-log).
bSI, stimulation index, geometrical mean of the experimental group divided by the geometrical mean of the control group. 
cP value vs. control value (c) as determined by Student’s t test; NS, not significant (P   0.05).T
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replacing C3b in the formation of alternative pathway C3
convertase resulting in CVFBb instead of C3bBb com-
plexes. Whereas C3bBb is relatively labile, CVFBb has a
half-life of several hours, resulting in transient C3-deple-
tion (production is not affected; reference 38). Normal
CBA/J mice were treated with CVF or sham-treated with
PBS. C3 levels in CVF-treated animals were  5% of the
titers in sham-treated mice (C3 titers   SEM: 2.3   0.25
vs. 49   9.5, respectively). Both groups were immunized
with BSA-TNP alone or in complex with 50  g IgG3
(IM-F10) and tested for BSA-specific IgG. C3-depletion
resulted in a significant reduction of responses to IgG3/
BSA-TNP complexes (Fig. 1, A and B). In contrast, C3-
depletion had no significant effect on responses to IgE/
BSA-TNP, included as a control (Fig. 1, C and D). IgE-
mediated enhancement is exclusively dependent on the
low affinity receptor for IgE, CD23 (15, 19, 20) and there-
fore operates independently of C. Although IgG3-medi-
ated enhancement was significantly impaired in CVF-
treated mice, it was not completely absent (Fig. 1 B). One
reason for this could be the residual levels of C3.
Cr2 /  mice respond normally to complexes consisting
of IgE/Ag and IgG2a/Ag whereas responses to IgM/Ag are
very low (17). To further test the C dependence of IgG3-
mediated enhancement, Cr2 /  and wild-type mice were
immunized with OVA-TNP alone or in complex with 50
 g IM-F10 (Fig. 2). IgG3-mediated enhancement was se-
verely impaired in Cr2 /  animals at all times tested. To
verify that the impaired responses to IgG3/OVA-TNP
were not just an effect of a general low-responsiveness,
Cr2 /  mice were immunized also with IgG2a/Ag (Fig.
3). Whereas IgG3-mediated enhancement decreased mark-
edly (SI   16 in wild-type mice and 5.6 in Cr2 /  mice),
IgG2a-mediated enhancement was stronger in Cr2 / 
mice (SI   17 in wild-type mice and 32 in Cr2 / ), thus
confirming earlier studies (17). The results show that IgG3,
but not IgG2a, loses most of its enhancing capacity in mice
lacking CD21/CD35. Unlike another Cr2 /  line, which
expresses a hypomorphic variant of CD21/CD35 (39), the
Cr2 /  line used here completely lacks expression of
CD21/CD31 (40). Therefore, the residual enhancement
seen in Cr2 /  mice (Fig. 2 B) cannot result from en-
hancement via a hypomorphic receptor.
Normal Ab Responses to IgG3/Ag Complexes in FcR  / 
Mice. Since a small enhancement by IgG3 could be de-
tected both in C3-depleted and Cr2 /  mice (Figs. 1–3),
we wanted to test whether Fc Rs may also be involved.
FcR  /  and FcR  /  mice were immunized with OVA-
TNP alone or in complex with IgG3 (IM-10). IgG3 en-
hanced the OVA-specific Ab response equally efficiently in
Figure 1. IgG3-, but not IgE-, mediated enhancement is impaired in
CVF-treated mice. Groups of five FcR  /  mice, treated with CVF or
sham-treated with PBS, were immunized intravenously with 20  g BSA-
TNP and 20  g OVA alone or in combination with 50  g TNP-specific
IgG3 (A and B) or IgE (C and D). On the indicated days, mice were bled
and the IgG anti-BSA and anti-OVA titers were measured by ELISA.
OVA-specific responses were not enhanced by IgG3 or IgE (unpublished
data). Asterisks indicate the statistical differences between experimental
and control groups within the same strain; asterisks within parentheses in-
dicate the statistical differences between corresponding not-C3-depleted
and C3-depleted groups. *, P   0.05; **, P   0.01; ***, P   0.001; NS,
not significant.
Figure 2. IgG3-mediated enhancement is impaired in Cr2 /  mice.
Groups of five Cr2 /  (A) and Cr2 /  (B) mice were immunized intrave-
nously with 20  g OVA-TNP and 20  g KLH alone or in combination
with 50  g TNP-specific IgG3. On the indicated days, mice were bled
and the IgG anti-OVA and anti-KLH titers were measured by ELISA.
KLH-specific responses were not enhanced by IgG3 (unpublished data).
Asterisks indicate the statistical differences between experimental and con-
trol groups within the same strain; asterisks within parentheses indicate the
statistical differences between the corresponding Cr2 /  and Cr2 / 
groups. *, P   0.05; **, P   0.01; ***, P   0.001; NS, not significant.T
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both strains (Fig. 4). These experiments were repeated using
BSA-TNP as the Ag and yielded similar results (unpub-
lished data). Thus, IgG3 enhances well in mice lacking ex-
pression of Fc RIII and with reduced expression of Fc RI.
Normal Ab Responses to IgG3/Ag Complexes in Fc RIIB / 
Mice. Enhancement by TNP-specific IgG1, IgG2a, and
IgG2b mAbs administered with BSA-TNP increases dramat-
ically in Fc RIIB /  mice compared with wild-type con-
trols (14). IgG3 is the only IgG subclass reported not to bind
to Fc RIIB and it was of interest to test whether IgG3-
mediated enhancement was indeed independent on this re-
ceptor. Wild-type and Fc RIIB /  mice were immunized
with BSA-TNP alone or in complex with 50  g IgG3
(IM-F10) and their sera tested for BSA-specific IgG. The Ab
responses were enhanced both in Fc RII /  (11–16-fold of
controls) and Fc RIIB /  mice (16–25-fold of controls; Fig.
5). Although IgG3 induced a twofold higher Ab response in
Fc RIIB /  compared with wild-type mice, this differ-
ence was not significant and was far less pronounced than
the 20–100-fold increased enhancement previously reported
with IgG1-, IgG2a-, and IgG2b-complexes (14). The re-
sponse to uncomplexed Ag is similar in Fc RIIB /  and
wild-type mice (Fig. 5). In light of the fact that immunization
with proteins without adjuvant induces very little production
of IgG, which is a prerequisite for ligation of Fc RIIB and
initiation of its negative regulation, this is not surprising. Thus,
IgG3-mediated enhancement takes place in the absence of
Fc RIIB and this receptor does not exert a significant inhibi-
tory influence on responses to IgG3-complexed Ags.
Discussion
Here we provide the first evidence that IgG3 can posi-
tively feedback-regulate Ab production. The augmentation
is impressive, frequently yielding several-hundred-fold in-
creases in Ab titers, and is severely impaired in mice lacking
CD21/CD35 or in mice with reduced C3 levels. It is well
Figure 3. IgG2a-mediated enhancement is normal in Cr2 /  mice.
Groups of five Cr2 /  (A) and Cr2 /  (B) mice were immunized intra-
venously with 20  g OVA-TNP and 20  g KLH alone or in combina-
tion with 50  g TNP-specific IgG3 or IgG2a. Mice were bled 14 d after
immunization and the IgG anti-OVA and anti-KLH titers were measured
by ELISA. KLH-specific responses were not enhanced by IgG3. Asterisks
indicate the statistical differences between experimental and control
groups. ***, P   0.001.
Figure 4. IgG3-mediated enhancement is normal in FcR  /  mice.
Groups of four FcR  /  and FcR  /  mice were immunized intrave-
nously with 20  g OVA-TNP and 20  g KLH alone or in combination
with 50  g TNP-specific IgG3. On the indicated days mice were bled
and the IgG anti-OVA and anti-KLH titers were measured by ELISA.
Anti-KLH responses were not enhanced by IgG3 (unpublished data). As-
terisks indicate the statistical differences between experimental and control
groups within the same strain; asterisks within parentheses indicate the sta-
tistical differences between the corresponding FcR  /  and FcR  / 
groups. * P   0.05; **, P   0.01; ***, P   0.001; NS, not significant.
Figure 5. IgG3-mediated enhancement is normal in Fc RIIB / 
mice. Groups of five Fc RIIB /  and Fc RIIB /  mice were immu-
nized intravenously with 20  g BSA-TNP and 20  g OVA alone or in
combination with 50  g TNP-specific IgG3. On the indicated days mice
were bled and the IgG anti-BSA and anti-OVA titers were measured by
ELISA. OVA-specific responses were not enhanced (unpublished data).
Asterisks indicate the statistical differences between experimental and
control groups within the same strain; asterisks within parentheses indi-
cate the statistical differences between the corresponding Fc RIIB / 
and Fc RIIB /  groups. *, P   0.05; **, P   0.01; ***, P   0.001; NS,
not significant.T
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known that C plays an important role for primary as well as
secondary Ab responses, and animals lacking C1q, C2, C4,
C3, as well as CD21/CD35 have severely impaired Ab re-
sponses (for reviews, see references 23 and 24). In contrast,
factor B–deficient mice have normal Ab responses (41; un-
published data) suggesting that the alternative pathway is
not required for up-regulation of Ab responses and that
classical pathway activation (via immune complexes) plays a
major role. One explanation for the role of C in Ab re-
sponses is that immune complexes, containing C factors,
cocrosslink BCR and the CD21/CD19-receptor complex
on the B cell surface and thereby lowers the threshold for B
cell activation, as shown to take place in vitro (25). A mu-
tually not exclusive hypothesis is that Ab/Ag/C complexes
are captured by follicular dendritic cells in the spleen and
lymph nodes, increasing the effective concentration of Ag
(22, 42, 43). Our present data suggest that not only IgM
(17, 21, 22), but also IgG3, uses the C system to initiate
feedback “help” for early Ab production. Since classical
pathway C activation is important for normal primary Ab
responses in animals immunized with Ag alone, an interest-
ing question is how specific Abs, able to recognize Ag and
form immune complexes, can be available in naive mice.
Mice lacking secretory IgM have impaired primary Ab re-
sponses to noncomplexed Ags (44–46) and a normal re-
sponse could be reconstituted by transfer of IgM from na-
ive mice. These animals may have several abnormalities in
their immune system, secondary to the lack of secretory
IgM, and were also reported to have developmental defects
in their B cell compartment (45, 47). The underlying rea-
son for the impaired IgG responses observed (44–46) is not
known. However, one intriguing explanation would be
that “natural” IgM, present without prior (deliberate) im-
munizations, initiates positive feedback of early responses.
Should the enhancing effect of natural IgM be caused by its
ability to activate C, which has not been formally proven,
it is possible that recognition of Ag by natural IgM is the
first step in the C-dependent chain of events leading to ef-
ficient early Ab responses to suboptimal doses of Ag. This
would explain how classical C activation can play a role al-
ready for primary Ab responses. Our present data raises the
question whether “natural” IgG3 has a similar role as IgM
in enhancing early Ab responses.
IgM has only been reported to enhance responses to
large Ags such as erythrocytes (21, 48), malaria parasites
(49), and KLH (22), whereas responses to small Ags, e.g.
BSA-TNP, have not been reported to be enhanced (un-
published data). An explanation for this would be that IgM
must bind to an Ag large enough to permit binding of sev-
eral of its arms in order to achieve the conformation change
necessary to bind C1q. IgG3, bound to the surface of e g
group A streptococci, is able to facilitate the binding of
other IgG3 molecules to the same Ag (50, 51). This so
called cooperative binding is probably mediated by Fc–Fc
interactions and increases the functional affinity of IgG3.
The interaction between IgG3 molecules is also evidenced
by their tendency to self-aggregate (52) and to act as cryo-
globulins, i.e. to precipitate in the cold (53). Cooperative
binding of IgG3 would increase the chances that two or
more IgG3 molecules end up close together (and thereby
can bind C1q) also on Ags which are too small for IgM to
bind with all five arms. This may explain why IgG3, but
not IgM, can utilize C to enhance responses to Ags like
BSA and OVA. The probability that two IgG2a or IgG2b
molecules, subclasses which do not show cooperative bind-
ing, bind to the same Ag close enough to be able to fix
C1q is smaller and could be the reason that these subclasses
preferentially utilize Fc Rs for feedback enhancement.
Unlike enhancement mediated by IgG1 and IgG2a,
IgG3-mediated enhancement was unperturbed in FcR  / 
mice. Although Fc RI in these animals has lost its signaling
function, 20% of the receptor is still expressed (11). As Fc-
 RI was also reported to bind IgG3 (10, 11), we cannot at
this point exclude that Fc RI, or another yet unidentified
IgG3-binding receptor, acts redundantly to C in IgG3-
mediated enhancement. This would explain the small re-
sidual enhancement seen in C-depleted and Cr2 /  mice.
Direct experiments to prove this point will have to await
the availability of Fc RI /  mice on a responder back-
ground, as H-2b mice, commonly used to produce knock-
out mice, are nonresponders to soluble IgE- and IgG-immune
complexes (28, 32).
Mice lacking Fc RIIB have augmented humoral, ana-
phylactic, and inflammatory immune responses (for a re-
view, see reference 54). This receptor contains a cyto-
plasmic immunoreceptor tyrosine-based inhibitory motif
(ITIM), which upon cocrosslinking to receptors containing
immunoreceptor tyrosine-based activation motifs (ITAMs),
such as the BCR, Fc RI, Fc RIII, and Fc RI, inhibits ac-
tivation of the ITAM receptor. Ab production after immu-
nization with IgG1/Ag, IgG2a/Ag, or IgG2b/Ag com-
plexes is considerably higher in Fc RIIB /  mice than in
wild-type controls, implying that Fc RIIB negatively reg-
ulates the response to Ag complexed to these isotypes (14).
IgG3 does not bind Fc RIIB and we here show that en-
hancement by IgG3 is similar in Fc RIIB /  and wild-
type mice. Therefore, IgG3/Ag complexes have the for
IgG isotypes unique possibility to enhance Ab responses
without inducing simultaneous negative feedback via
cocrosslinking of BCR and Fc RIIB. This feature may be
useful to quickly generate a potent primary Ab response to
e g bacterial Ags. IgG3 is an isotype frequently involved in
autoimmunity (55–58). In addition to its ability to initiate
inflammation via C-activation, the ability of IgG3 to en-
hance autoantibody production without negative feedback
via Fc RIIB may play a role in its pathogenicity.
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